Nerve conduction studies in selected peripheral nerve disorders

Current Opinion in Neurology

Volumn 15, Issue 5, 2002, Pages 579-593

  Krarup, Christian ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Axonal degeneration; Compound muscle action potential; Compound sensory action potential; Conduction velocity; Demyelination; Electrophysiology; Excitability; Nerve conduction studies

Indexed keywords

ION CHANNEL; MYELIN;

CLASSIFICATION; CRITICAL ILLNESS; ELECTRODIAGNOSIS; ELECTROPHYSIOLOGY; HUMAN; MUSCLE ACTION POTENTIAL; NERVE CONDUCTION; NERVE EXCITABILITY; NERVE FIBER DEGENERATION; NERVE FIBER MEMBRANE; NEUROMUSCULAR DISEASE; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; AXONS; ELECTROPHYSIOLOGY; HUMANS; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 0036798907     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200210000-00009     Document Type: Review

References (165)

1. Rutkove SB. Effects of temperature on neuromuscular electrophysiology. Muscle Nerve 2001; 24:867-882.
2. Behse F, Buchthal F. Sensory action potentials and biopsy of the sural nerve in neuropathy. Brain 1978; 101:473-493.
3. Buchthal F, Rosenfalck A. Sensory potentials in polyneuropathy. Brain 1971; 94:241-262.
4. Koike H, Mori K, Misu K, et al. Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology 2001; 56:1727-1732.
5. Smith AG, Ramachandran P, Tripp S, et al. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology 2001; 57:1701-1704.
6. Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999; 52:498-503.
7. Ohkoshi N, Harada K, Nagata H, et al. Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy: clinical features and pathological study of the sural nerves. Eur Neurol 2001; 45:241-248.
8. Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol 2002; 249:245-253.
9. Killian JM, Foreman PJ. Clinical utility of dorsal sural nerve conduction studies. Muscle Nerve 2001; 24:817-820.
10. Oh SJ, Melo AC, Lee DK, et al. Large-fiber neuropathy in distal sensory neuropathy with normal routine nerve conduction. Neurology 2001; 56:1570-1572.
11. Baba M, Simonetti S, Krarup C. Sensory potentials evoked by tactile stimulation of different indentation velocities at the finger and palm. Muscle Nerve 2001; 24:1213-1218.
12. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, et al. Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain 1993; 116:1017-1041.
13. Inaba A, Yokota T, Saito Y, et al. Proximal motor conduction evaluated by transcranial magnetic stimulation in acquired inflammatory demyelinating neuropathies. Clin Neurophysiol 2001; 112:1936-1945.
14. Inaba A, Yokota T, Otagiri A, et al. Electrophysiological evaluation of conduction in the most proximal motor root segment. Muscle Nerve 2002; 25:606-611.
15. Kuwabara S, Cappelen-Smith C, Lin CS, et al. Effects of voluntary activity on the excitability of motor axons in the peroneal nerve. Muscle Nerve 2002; 25:176-184.
16. Kaji R, Suzumura A, Sumner AJ. Physiological consequences of antiserum-mediated experimental demyelination in CNS. Brain 1988; 111:675-694.
17. Miller TA, Kiernan MC, Mogyoros I, et al. Activity-dependent changes in impulse conduction in a focal nerve lesion. Brain 1996; 119:429-437.
18. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000; 55:1256-1262.
19. Havton LA, Hotson JR, Kellerth JO. Partial peripheral motor nerve lesions induce changes in the conduction properties of remaining intact motoneurons. Muscle Nerve 2001; 24:662-666.
20. Sabatelli M, Madia F, Mignogna T, et al. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol 2001; 248:772-777.
21. Shefner JM. Motor unit number estimation in human neurological diseases and animal models. Clin Neurophysiol 2001; 112:955-964.
22. Krarup C, Archibald SJ, Madison RD. Factors that influence peripheral nerve regeneration: an electrophysiological study of the monkey median nerve. Ann Neurol 2002; 51:69-81.
23. Cuturic M, Palliyath S. Motor unit number estimate (MUNE) testing in male patients with mild to moderate carpal tunnel syndrome. Electromyogr Clin Neurophysiol 2000; 40:67-72.
24. Olney RK, Yuen EC, Engstrom JW. Statistical motor unit number estimation: reproducibility and sources of error in patients with amyotrophic lateral sclerosis. Muscle Nerve 2000; 23:193-197.
25. Kuwabara S, Ogawara K, Mizobuchi K, et al. Mechanisms of early and late recovery in acute motor axonal neuropathy. Muscle Nerve 2001; 24:288-291.
26. Behse F, Buchthal F. Peroneal muscular atrophy (PMA) and related disorders. II. Histological findings in sural nerves. Brain 1977; 100:67-85.
27. Gherardi R, Bouche P, Escourolle R, et al. Peroneal muscular atrophy. Part 2. Nerve biopsy studies. J Neurol Sci 1983; 61:401-416.
28. Lunn MP, Crawford TO, Hughes RA, et al. Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. Brain 2002; 125:904-911.
29. Starr R, Attema B, Devries GH, et al. Neurofilament phosphorylation is modulated by myelination. J Neurosci Res 1996; 44:328-337.
30. Witt A, Brady ST. Unwrapping new layers of complexity in axon/glial relationships. Glia 2000; 29:112-117.
31. Feasby TE, Hahn AF, Brown WF, et al. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms? J Neurol Sci 1993; 116:185-192.
32. Fuller GN, Jacobs JM, Lewis PD, et al. Pseudoaxonal Guillain-Barré syndrome: severe demyelination mimicking axonopathy. A case with pupillary involvement. J Neurol Neurosurg Psychiatry 1992; 55:1079-1083.
33. Meulstee J, Darbas A, Van Doorn PA, et al. Decreased electrical excitability of peripheral nerves in demyelinating polyneuropathies. J Neurol Neurosurg Psychiatry 1997; 62:398-400.
34. Albers JW, Kelly JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989; 12:435-451.
35. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27 (Suppl):S21-S24.
36. Cornblath DR, Asbury AK, Albers JW, et al. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991; 41:617-618.
37. Lewis RA, Sumner AJ, Brown MJ, et al. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982; 32:958-964.
38. Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology 1982; 32:592-596.
39. Kuwabara S, Ogawara K, Misawa S, et al. Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002; 72:37-42.
40. Stoll G, Hartung H-P. The role of macrophages in degeneration and immune-mediated demyelination of the peripheral nervous system. Adv Neuroimmunol 1992; 2:163-179.
41. Willison H, Stoll G, Toyka KV, et al. Autoimmunity and inflammation in the peripheral nervous system. Trends Neurosci 2002; 25:127-129.
42. Lafontaine S, Rasminsky M, Saida T, et al. Conduction block in rat myelinated fibres following acute exposure to anti-galactocerebroside serum. J Physiol (London) 1982; 323:287-306.
43. Watson BV, Parkes AW, Brown JD. Transient forearm conduction block in the median nerve. Muscle Nerve 2002; 25:456-460.
44. Hirota N, Kaji R, Bostock H, et al. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain 1997; 120:2159-2169.
45. Smith KJ, Kapoor R, Hall SM, et al. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001; 49:470-476.
46. Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barré polyneuropathy. Brain 1984; 107:219-239.
47. van der Meché FGA, Vermeulen M, Busch HFM. Chronic inflammatory demyelinating polyneuropathy. Conduction failure before and during immunoglobulin or plasma therapy. Brain 1989; 112:1563-1571.
48. Krarup C, Stewart JD, Sumner AJ, et al. A syndrome of asymmetric limb weakness with motor conduction block. Neurology 1990; 40:118-127.
49. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001; 115:4-18.
50. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:195-201.
51. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56:445-449.
52. Rhee EK, England JD, Sumner AJ. A computer simulation of conduction block: effects produced by actual block versus interphase cancellation. Ann Neurol 1990; 28:146-156.
53. Kaji R, Kimura J, Nerve conduction block. Curr Opin Neurol Neurosurg 1991; 4:744-748.
54. Nicolas G, Maisonobe T, Le Forestier N, et al. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002; 25:26-30.
55. Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: electrodiagnostic features. Muscle Nerve 1994; 17:198-205.
56. Lange DJ, Trojaborg W, Latov N, et al. Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? Neurology 1992; 42:497-505.
57. Eurelings M, Ang CW, Notermans NC, et al. Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy. Neurology 2001; 57:1909-1912.
58. Krarup C, Trojaborg W. Sensory pathophysiology in chronic acquired demyelinating neuropathy. Brain 1996; 119:257-270.
59. Cornblath DR, Sumner AJ, Daube J, et al. Conduction block in clinical practice. Muscle Nerve 1991; 14:869-871.
60. Olney RK. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve 1999; 22:S225-S229.
61. Pfeiffer G, Wicklein EM, Wittig K, Sensitivity and specificity of different conduction block criteria. Clin Neurophysiol 2000; 111:1388-1394.
62. Cappelen-Smith C, Kuwabara S, Lin CS, et al. Membrane properties in chronic inflammatory demyelinating polyneuropathy. Brain 2001; 124:2439-2447.
63. Padua L, Aprile I, D'Amico P, et al. A useful electrophysiological test for diagnosis of minimal conduction block. Clin Neurophysiol 2001; 112:1041-1048.
64. Rosenberg NR, Portegies P, de Visser M, et al. Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline. J Neurol Neurosurg Psychiatry 2001; 71:205-209.
65. Jann S, Beretta S, Bramerio M, et al. Prospective follow-up study of chronic polyneuropathy of undetermined cause. Muscle Nerve 2001; 24:1197-1201.
66. Suarez GA, Chalk CH, Russell JW, et al. Diagnostic accuracy and certainty from sequential evaluations in peripheral neuropathy. Neurology 2001; 57:1118-1120.
67. Hughes RAC. Diagnosis of chronic peripheral neuropathy. J Neurol Neurosurg Psychiatry 2001; 71:147-148.
68. Hughes RAC. Peripheral neuropathy. Br Med J 2002; 324:466-469.
69. Said G. Vasculitic neuropathies. In: Latov N, Wokke JHJ, Kelly JJ, editors. Immunological and infectious diseases of the peripheral nerves. Cambridge: Cambridge University Press; 1998. pp. 158-167.
70. Verghese J, Bieri PL, Gellido C, et al. Peripheral neuropathy in young-old and old-old patients. Muscle Nerve 2001; 24:1476-1481.
71. Said G, Goulongoeau C, Lacroix C, et al. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994; 35:559-569.
72. Said G, Elgrably F, Lacroix C, et al. Painful proximal diabetic neuropathy: inflammatory nerve lesions and spontaneous favorable outcome. Ann Neurol 1997; 41:762-770.
73. Walters RJ, Murray NM. Transcarpal motor conduction velocity in carpal tunnel syndrome. Muscle Nerve 2001; 24:966-968.
74. Wee AS. Carpal tunnel syndrome: a system for categorizing and grading electrophysiologic abnormalities. Electromyogr Clin Neurophysiol 2001; 41:281-288.
75. Bland JD. Do nerve conduction studies predict the outcome of carpal tunnel decompression? Muscle Nerve 2001; 24:935-940.
76. Uchiyama S, Toriumi H, Nakagawa H, et al. Postoperative nerve conduction changes after open and endoscopic carpal tunnel release. Clin Neurophysiol 2002; 113:64-70.
77. Bodofsky EB, Greenberg WM, Wu KD. Median nerve compression at the wrist: is it ever unilateral? Electromyogr Clin Neurophysiol 2001; 41:451-456.
78. Perkins BA, Olaleye D, Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care 2002; 25:565-569.
79. Collins MP, Mendell JR, Periquet MI, et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 2000; 55:636-643.
80. Sandbrink F, Klion AD, Floeter MK. "Pseudo-conduction block" in a patient with vasculitic neuropathy. Electromyogr Clin Neurophysiol 2001; 41:195-202.
81. Michel P, Miklossy J, Kuntzer T. Peripheral axonal motor degeneration after spinal cord infarct. J Neurol Neurosurg Psychiatry 2002; 71:128.
82. Said G, Lacroix C, Planté-Bordeneuve V, et al. Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients. Brain 2002; 125:264-275.
83. de Groot K, Schmidt DK, Arlt AC, et al. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001; 58:1215-1221.
84. Pleasure D. Peripheral neuropathy as the first clinical manifestation of Wegener granulomatosis [Editorial]. Arch Neurol 2001; 58:1204.
85. Cacoub P, Maisonobe T, Thibault V, et al. Systemic vasculitis in patients with hepatitis C. J Rheumatol 2001; 28:109-118.
86. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998; 44:780-788.
87. Oh SJ, LaGanke C, Claussen GC. Sensory Guillain-Barré syndrome. Neurology 2001; 56:82-86.
88. Kuwabara S, Mori M, Ogawara K, et al. Intravenous immunoglobulin therapy for Guillain-Barré syndrome with lgG anti-GM1 antibody. Muscle Nerve 2001; 24:54-58.
89. Hughes RAC. Sensory form of Guillain-Barré syndrome [commentary]. Lancet 2001; 357:1465.
90. Serrano-Munuera C, Gallardo E, Rojas R, et al. Antiganglioside antibodies in acute self-limiting ataxic neuropathy: incidence and significance. J Neuroimmunol 2001; 120:78-83.
91. Camdessanché JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 2002; 125:166-175.
92. Barendregt PJ, van den Bent M , van Raaij-van den Aarssen VJ, et al. Involvement of the peripheral nervous system in primary Sjögren's syndrome. Ann Rheum Dis 2001; 60:876-881.
93. Chen WH, Yeh JH, Chiu HC. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjögren's syndrome. Eur Neurol 2001; 45:270-274.
94. Oshima Y, Mitsui T, Endo I, et al. Corticospinal tract involvement in a variant of Guillain-Barré syndrome. Eur Neurol 2001; 46:39-42.
95. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001; 58:913-917.
96. Green DM, Ropper AH. Mild Guillain-Barré syndrome. Arch Neurol 2001; 58:1098-1101.
97. Van Koningsveld R, Schmitz PI, Ang CW, et al. Infections and course of disease in mild forms of Guillain-Barré syndrome. Neurology 2002; 58:610-614.
98. Katsuno M, Ando T, Hakusui S, et al. Motor conduction studies in Miller Fisher syndrome with severe tetraparesis. Muscle Nerve 2002; 25:378-382.
99. O'Hanlon GM, Plomp JJ, Chakrabarti M, et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 2001; 124:893-906.
100. Wirguin I, Ifergane G, Almog Y, et al. Presynaptic neuromuscular transmission block in Guillain-Barré syndrome associated with anti-GQ1(b) antibodies. Neuromuscul Disord 2002; 12:292-293.
101. Arai M, Odaka M, Yuki N, et al. A patient with overlapping Bickerstaff's brainstem encephalitis, Miller Fisher syndrome and Guillain-Barré syndrome during the clinical course. Eur J Neurol 2002; 9:115-116.
102. Lo YL, Ratnagopal P. Transcranial magnetic stimulation studies in the Miller Fisher syndrome: evidence of corticospinal tract abnormality. J Neurol Neurosurg Psychiatry 2001; 71:210-214.
103. Dabby R, Weimer LH, Hays AP, et al. Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates. Neurology 2000; 54:1448-1452.
104. Eurelings M, Moons KG, Notermans NC, et al. Neuropathy and lgM M-proteins: prognostic value of antibodies to MAG, SGPG, and sulfatide. Neurology 2001; 56:228-233.
105. Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001; 184:57-63.
106. Yan WX, Archelos JJ, Hartung HP, et al. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:286-292.
107. Hughes RA. Chronic inflammatory demyelinating polyradiculoneuropathy [editorial]. Ann Neurol 2001; 50:281-282.
108. Rotta FT, Sussman AT, Bradley WG, et al. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000; 173:129-139.
109. Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000; 54:615-620.
110. Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24:311-324.
111. Katz JS, Barohn RJ, Krojan S, et al. Axonal multifocal motor neuropathy without conduction block or other features of demyelination. Neurology 2002; 58:615-620.
112. Molenaar DSM, Vermeulen M, de Haan RJ. Comparison of electrodiagnostic criteria for demyelination in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol 2002; 249:400-403.
113. Eurelings M, Notermans NC, Van de Donk NW, et al. Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy. Muscle Nerve 2001; 24:1295-1302.
114. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994; 117:941-947.
115. Lawlor MW, Richards MP, Fisher MA, et al. Sensory nerve conduction deficit in experimental monoclonal gammopathy of undetermined significance (MGUS) neuropathy. Muscle Nerve 2001; 24:809-816.
116. Attarian S, Azulay JP, Boucraut J, et al. Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies. Clin Neurophysiol 2001; 112:457-463.
117. Cocito D, Isoardo G, Ciaramitaro P, et al. Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAC antibody. Muscle Nerve 2001; 24:1278-1282.
118. Gorson KC, Ropper AH, Weinberg DH, et al. Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 2001; 24:778-786.
119. Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAC IgM M-proteins and its relationship to immune therapies. Brain 2000; 123:710-717.
120. Antoine JC, Honnorat J, Camdessanché JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49:214-221.
121. Honnorat J, Antoine JC, Belin MF. Are the 'newly discovered' paraneoplastic anticollapsin response-mediator protein 5 antibodies simply anti-CV2 antibodies? Ann Neurol 2001; 50:688-691.
122. Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146-154.
123. Bolton CF, Gilbert JJ, Hahn AF, et al. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry 1984; 47:1223-1231.
124. Bolton CF, Laverty DA, Brown JD, et al. Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1986; 49:563-573.
125. Zochodne DW, Bolton CF, Wells GA, et al. Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. Brain 1987; 110:819-841.
126. Kane SL, Dasta JF. Clinical outcomes of critical illness polyneuropathy. Pharmacotherapy 2002; 22:373-379.
127. Zifko UA. Long-term outcome of critical illness polyneuropathy. Muscle Nerve 2000; 9(Suppl):S49-S53.
128. de Letter MACJ, Schmitz PIM, Visser LH, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001; 29:2281-2286.
129. Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia JL, et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med 2001; 27:1288-1296.
130. Op de Coul AAW, Verheul GAM, Leyten ACM, et al. Critical illness polyneuromyopathy after artificial respiration. Clin Neurol Neurosurg 1991; 93:27-33.
131. Magistris MR. Critical illness neuropathies. Rev Neurol (Paris) 2002; 158:293-299.
132. Tepper M, Rakic S, Haas JA, et al. Incidence and onset of critical illness polyneuropathy in patients with septic shock. Neth J Med 2000; 56:211-214.
133. de Letter MACJ, Visser LH, van tier Meché FGA, et al. Distinctions between critical illness polyneuropathy and axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2000; 68:397-398.
134. Yuki N, Hirata K. Relation between critical illness polyneuropathy and axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1999; 67:128-129.
135. Druschky A, Herkert M, Radespiel-Troger M, et al. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med 2001; 27:686-693.
136. de Letter MACJ, Van Doorn PA, Savelkoul HFJ, et al. Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol 2000; 106:206-213.
137. Höke A, Rewcastle NB, Zochodne DW. Acute quadriplegic myopathy unrelated to steroids or paralyzing agents: quantitative EMG studies. Can J Neurol Sci 1999; 26:325-329.
138. Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve 1998; 21:610-617.
139. Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet 1996; 347:1579-1582.
140. Trojaborg W, Weimer LH, Hays AP. Electrophysiologic studies in critical illness associated weakness: myopathy or neuropathy: a reappraisal. Clin Neurophysiol 2001; 112:1586-1593.
141. Zifko UA, Zipko HT, Bolton CF. Clinical and electrophysiological findings in critical illness polyneuropathy. J Neurol Sci 1998; 159:186-193.
142. Bolton CF. Critical illness polyneuropathy and myopathy. Crit Care Med 2001; 29:2388-2390.
143. Schwarz J, Planck J, Briegel J, et al. Single-fiber electromyography, nerve conduction studies, and conventional electromyography in patients with critical-illness polyneuropathy: evidence for a lesion of terminal motor axons. Muscle Nerve 1997; 20:696-701.
144. Kuipers-Upmeijer J, De Jager AE, Hew JM, et al. Primary lateral sclerosis: clinical, neurophysiological, and magnetic resonance findings. J Neurol Neurosurg Psychiatry 2001; 71:615-620.
145. Le Forestier N, Maisonobe T, Piquard A, et al. Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain 2001; 124:1989-1999.
146. Moulignier A, Moulonguet A, Pialoux G, et al. Reversible ALS-like disorder in HIV infection. Neurology 2001; 57:995-1001.
147. Ho TW, Hsieh ST, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997; 48:717-724.
148. Ho TW, Li CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barré syndromes. Neurology 1997; 48:695-700.
149. Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997; 23:1144-1149.
150. Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998; 21:137-158.
151. Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol 2001; 112:1575-1585.
152. Kiernan MC, Burke D, Andersen KV, et al. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000; 23:399-409.
153. Shefner JM. Excitability testing in clinical neurophysiology: what, why, and when? Muscle Nerve 2001; 24:845-847.
154. Kiernan MC, Lin CSY, Andersen KV, et al. Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve 2001; 24:883-892.
155. Kiernan MC, Cikurel K, Bostock H. Effects of temperature on the excitability properties of human motor axons. Brain 2001; 124:816-825.
156. Kuwabara S, Lin CS, Mogyoros I, et al. Voluntary contraction impairs the refractory period of transmission in healthy human axons. J Physiol 2001; 531:265-275.
157. Kuwabara S, Cappelen-Smith C, Lin CS, et al. Differences in accommodative properties of median and peroneal motor axons. J Neurol Neurosurg Psychiatry 2001; 70:372-376.
158. Lin CS, Mogyoros I, Kuwabara S, et al. Differences in responses of cutaneous afferents in the human median and sural nerves to ischemia. Muscle Nerve 2001; 24:1503-1509.
159. Waiters RJL, Kiernan MC, Murray NMF, et al. Distal excitability properties of median motor axons. Muscle Nerve 2001; 24:1695-1698.
160. Yang Q, Kaji R, Takagi T, et al. Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy. Brain 2001; 124:1149-1155.
161. Kiernan MC, Guglielmi JM, Kaji R, et al. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 2002; 125:664-675.
162. Krarup C, Moldovan M, Boeckstyns MEH, et al. Long-term excitability recovery in regenerating motor nerve fibers of cats and humans [abstract]. Clinical Neurophysiology 2000; 111:S129.
163. Moldovan M, Sørensen J, Krarup C. Excitability indices in long term regenerating crushed motor axons of cat after ischaemia and cooling [abstract]. Soc Neurosci 2001; 27:366.
164. Moldovan M, Sørensen J, Krarup C. Threshold electrotonus in regenerated motor fibers of cat. J Peripher Nerv Syst 1999; 4:186-187.
165. Yang Q, Kaji R, Hirota N, et al. Effect of maturation on nerve excitability in an experimental model of threshold electrotonus. Muscle Nerve 2000; 23:498-506.